[Form 4] Blueprint Medicines Corporation Insider Trading Activity

Rhea-AI Filing Summary

Conagra Brands EVP & Chief Supply Chain Officer Alexandre Eboli filed a Form 4 for transactions between 17 and 20 Jul 2025.

• Common stock: 37,091 shares were issued via long-term incentive and RSU vesting, while 14,351 shares were withheld for taxes at ≈$19, yielding a net gain of 22,740 shares. Direct ownership now stands at 52,771 shares.
• Derivative securities: A new award of 36,022 restricted stock units (RSUs) was granted; these vest 33.33 % on 17 Jul 2026 and 2027 and 33.34 % on 17 Jul 2028. After converting earlier awards, Eboli retains 36,022 unvested RSUs.

No open-market sales occurred—disposals were strictly tax withholdings. The filing reflects routine equity compensation activity that modestly increases the insider’s exposure to CAG shares.

Positive

• Net increase of 22,740 shares in direct ownership, enhancing management–shareholder alignment.
• 36,022 new RSUs granted, providing additional long-term equity incentives.

Negative

• 14,351 shares disposed for tax withholding, adding minor share supply though not via open-market sale.

Insights

Equity Compensation Analyst

TL;DR: Routine vesting & grant; insider stake up 22.7K shares, no market sales—neutral valuation impact.

The transactions are standard compensation events. Performance shares and earlier RSUs settled into 37,091 new shares, of which 14,351 were automatically surrendered for tax withholding at ≈$19. Net direct ownership rises 76 % to 52,771 shares, aligning the EVP more closely with investors but without cash outlay. The fresh 36,022-unit RSU grant extends equity incentives through FY 2028, encouraging long-term retention. Because no discretionary buying or selling occurred, signal strength is modest and unlikely to shift market perception; therefore I classify the impact as neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Landsittel Michael

(Last) (First) (Middle)

C/O BLUEPRINT MEDICINES CORPORATION

45 SIDNEY STREET

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Blueprint Medicines Corp [ BPMC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/17/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/17/2025		A(1)(2)		21,353	A	(3)	94,277	D
Common Stock	07/17/2025		D(1)(2)		51,102	D	(3)(4)	43,175	D
Common Stock	07/17/2025		U(1)(2)		43,175	D	(5)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$15.01	07/17/2025		D(1)(2)			10,000	(6)	(6)	Common Stock	10,000	(6)	0	D
Stock Option (Right to Buy)	$81.44	07/17/2025		D(1)(2)			26,000	(6)	(6)	Common Stock	26,000	(6)	0	D
Stock Option (Right to Buy)	$86.6	07/17/2025		D(1)(2)			19,500	(6)	(6)	Common Stock	19,500	(6)	0	D
Stock Option (Right to Buy)	$54.13	07/17/2025		D(1)(2)			25,000	(6)	(6)	Common Stock	25,000	(6)	0	D
Stock Option (Right to Buy)	$100.13	07/17/2025		D(1)(2)			26,125	(6)	(6)	Common Stock	26,125	(6)	0	D
Stock Option (Right to Buy)	$61.31	07/17/2025		D(1)(2)			25,000	(6)	(6)	Common Stock	25,000	(6)	0	D
Stock Option (Right to Buy)	$43.15	07/17/2025		D(1)(2)			25,000	(6)	(6)	Common Stock	25,000	(6)	0	D
Stock Option (Right to Buy)	$95.12	07/17/2025		D(1)(2)			25,000	(6)	(6)	Common Stock	25,000	(6)	0	D
Stock Option (Right to Buy)	$96.57	07/17/2025		D(1)(2)			22,000	(6)	(6)	Common Stock	22,000	(6)	0	D

Explanation of Responses:

1. This Form 4 reports securities transacted pursuant to the Agreement and Plan of Merger (the "Merger Agreement") by and among the Issuer, SANOFI, a French societe anonyme ("Parent"), Aventis Inc., a Pennsylvania corporation and wholly owned subsidiary of Parent ("Aventis"), and Rothko Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Aventis ("Purchaser").

2. Pursuant to the Merger Agreement, Purchaser completed a tender offer to acquire all of the issued and outstanding shares of common stock of the Issuer, par value $0.001 per share (the "Common Stock"), for (i) $129.00 per share, without interest (the "Cash Offer Price"), plus (ii) one (1) contractual contingent value right per share, representing the right to receive contingent payments in cash, without interest, upon the achievement of certain milestones (each a "CVR" and together with the Cash Offer Price, the "Offer Consideration"). On July 17, 2025 (the "Effective Time"), Purchaser merged with and into the Issuer, with the Issuer surviving as an indirect wholly owned subsidiary of Parent.

3. Represents shares previously granted to the Reporting Person subject to performance-based vesting conditions ("PSUs"), for which the performance conditions associated with such PSUs had not yet occurred. As of the Effective Time, each PSU was deemed earned based on the greater of target and actual performance as of the Effective Time. Pursuant to the terms of the Merger Agreement, at the Effective Time, each PSU was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such PSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

4. Pursuant to the terms of the Merger Agreement, at the Effective Time, each outstanding restricted stock unit ("RSU"), whether vested or unvested, was cancelled and automatically converted into the right to receive the Offer Consideration, except that fifty percent of such RSUs that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price, plus one CVR for each share underlying such portion of the award.

5. Pursuant to the terms of the Merger Agreement, at the Effective Time, each share of Common Stock held by the Reporting Person was tendered in exchange for the Offer Consideration.

6. Pursuant to the terms of the Merger Agreement, at the Effective Time, each stock option that was outstanding, whether vested or unvested, immediately prior to the Effective Time became fully vested and was cancelled and converted into the right to receive for each share subject to such stock option (i) the Cash Offer Price (less the applicable exercise price per share subject to such option) and (ii) one (1) CVR (in each case, without interest and less applicable tax withholdings), except that fifty percent of such options that were issued in calendar year 2025 were converted into cash-based awards subject to continued vesting as described in the Merger Agreement based on the Cash Offer Price (less the applicable exercise price per share subject to such option), plus one CVR for each share underlying such portion of the option.

	/s/ Melissa Masse, Attorney-in-Fact	07/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many CAG shares did EVP Alexandre Eboli acquire in July 2025?

He acquired 37,091 shares through performance awards and RSU vesting.

What is Eboli's total direct ownership after these transactions?

His direct holdings stand at 52,771 CAG shares.

Were any shares sold on the open market?

No. Shares marked "F" were withheld solely for taxes; no open-market sales occurred.

How many new restricted stock units were granted to Eboli?

He received 36,022 new RSUs on 17 Jul 2025.

When do the newly granted RSUs vest?

They vest 33.33 % on 7/17/2026, 33.33 % on 7/17/2027 and 33.34 % on 7/17/2028.